Explore All 3109 Divestiture Life Science Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | January 6, 2022 |
| Target | Saol Therapeutics - Baclofen Franchise |
| Sector | Life Science |
| Sellers(s) | Saol Therapeutics |
| Deal Type | Divestiture |
FILTER BY
Saol Therapeutics is a privately held specialty pharmaceutical company focused on providing therapies to patients with rare diseases. Saol Therapeutics has a strategic emphasis on the neurology therapeutic area. Saol Therapeutics was founded in 2015 and is based in Roswell, Georgia.
| Deal Context for Seller | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science | 1 of 1 |
| Type: Divestiture | 1 of 1 |
| State: Georgia | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2022 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-08-31 |
Aptevo Therapeutics - Hyperimmune Commercial Products
Seattle, Washington, United States Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products comprises WinRho SDF, HepaGam B, and VARIZIG. WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems. |
Buy | $75M |
